Efficacy of Almonertinib Versus Osimertinib as the First-Line Treatment for Non-Small Cell Lung Cancer With EGFR L858R Mutation and Prognostic Analysis: A Retrospective Comparative Cohort Study
{{output}}
Objectives: Epidermal growth factor receptor (EGFR)-specific tyrosine kinase inhibitors show less efficacy against the EGFR L858R mutation than EGFR 19del, but no current head-to-head clinical trials have been performed comparing... ...
